I-MAB ADS overview

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35 th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025. Details are as follows: Oppenheimer’s 35 th Annual Healthcare Life Sciences Conference Conference...

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in a poster session scheduled for June 1, 2024 at 9:00...

LOS ANGELES, CA / ACCESSWIRE / September 1, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofI-Mab ("I-Mab" or "the Company") (NASDAQ:IMAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. I-Mab admitted in a August 16, 2022, SEC filing that collaboration partner...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofI-Mab ("I-Mab" or "the Company") (NASDAQ: IMAB ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. I-Mab admitted in a August 16, 2022, SEC filing that collaboration partner...

SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on proprietary and highly differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) has been selected for detailed poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting,...

SHANGHAI, China and GAITHERSBURG, Md. and SEONGNAM, South Korea, April 06, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the first patient has been dosed in a phase 1 trial for bispecific antibody...

SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, today announced its participation in the following conferences in April. Details of the conferences and management presentation are as follows: 20th Annual Needham Healthcare Conference (Virtual) Presentation: Tuesday, April 13, 2021 at 8:45 a.m. ET Presenter: Dr....

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for initiating phase 1 trial for...